Emerging technology and platforms for cardiotoxicity testing.
作者信息
Mohamed Tamer M A, Conklin Daniel J
机构信息
Institute of Molecular Cardiology, University of Louisville, Louisville, KY 40292, United States; Diabetes and Obesity Center, University of Louisville, Louisville, KY 40292, United States; Christina Lee Brown Envirome Institute, University of Louisville, Louisville, KY 40292, United States; Department of Medicine, University of Louisville, Louisville, KY 40292, United States.
Diabetes and Obesity Center, University of Louisville, Louisville, KY 40292, United States; Christina Lee Brown Envirome Institute, University of Louisville, Louisville, KY 40292, United States; Department of Medicine, University of Louisville, Louisville, KY 40292, United States.
出版信息
Toxicol Appl Pharmacol. 2020 Dec 1;408:115262. doi: 10.1016/j.taap.2020.115262. Epub 2020 Oct 2.
Abstract
摘要
相似文献
1
Emerging technology and platforms for cardiotoxicity testing.用于心脏毒性测试的新兴技术和平台。
Toxicol Appl Pharmacol. 2020 Dec 1;408:115262. doi: 10.1016/j.taap.2020.115262. Epub 2020 Oct 2.
2
Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.人诱导多能干细胞-心脏内皮肿瘤芯片用于评估抗癌疗效和心脏毒性。
Tissue Eng Part C Methods. 2020 Jan;26(1):44-55. doi: 10.1089/ten.TEC.2019.0248. Epub 2020 Jan 3.
3
In vitro cardiotoxicity assessment of environmental chemicals using an organotypic human induced pluripotent stem cell-derived model.使用器官型人诱导多能干细胞衍生模型对环境化学物质进行体外心脏毒性评估。
Toxicol Appl Pharmacol. 2017 May 1;322:60-74. doi: 10.1016/j.taap.2017.02.020. Epub 2017 Mar 1.
4
Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes.基于细胞的二维形态评估系统，使用人诱导多能干细胞衍生的心肌细胞预测癌症药物诱导的心脏毒性。
Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
5
Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings.抗癌药物所致心脏毒性分子靶点的见解：基于蛋白质组学研究结果的系统评价
Metabolism. 2022 Sep;134:155250. doi: 10.1016/j.metabol.2022.155250. Epub 2022 Jul 6.
6
Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.超越全面的体外致心律失常检测：利用人诱导多能干细胞衍生的心肌细胞评估与药物诱导的结构性心脏毒性相关的收缩作用。
J Appl Toxicol. 2018 Sep;38(9):1166-1176. doi: 10.1002/jat.3611. Epub 2018 Feb 27.
7
Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs.心肌毒性和心力衰竭：人诱导多能干细胞衍生心肌细胞和抗癌药物的教训。
Cells. 2020 Apr 17;9(4):1001. doi: 10.3390/cells9041001.
8
Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.应用微电极阵列（MEA）记录技术，用人诱导多能干细胞（iPSC）衍生的心肌细胞对非法药物和新型精神活性物质（NPS）进行心脏毒性筛选。
J Mol Cell Cardiol. 2019 Nov;136:102-112. doi: 10.1016/j.yjmcc.2019.09.007. Epub 2019 Sep 14.
9
Stem Cell-Derived Immature Human Dorsal Root Ganglia Neurons to Identify Peripheral Neurotoxicants.利用干细胞衍生的未成熟人类背根神经节神经元鉴定外周神经毒物。
Stem Cells Transl Med. 2016 Apr;5(4):476-87. doi: 10.5966/sctm.2015-0108. Epub 2016 Mar 1.
10
Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.人诱导多能干细胞衍生心肌细胞在临床前癌症药物心脏毒性检测中的应用：美国心脏协会的科学声明。
Circ Res. 2019 Oct 25;125(10):e75-e92. doi: 10.1161/RES.0000000000000291. Epub 2019 Sep 19.
本文引用的文献
1
Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity.心脏切片培养系统能可靠地显示临床药物相关性心脏毒性。
Toxicol Appl Pharmacol. 2020 Nov 1;406:115213. doi: 10.1016/j.taap.2020.115213. Epub 2020 Aug 30.
2
A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.一种比较阿霉素心脏保护剂右雷佐生（ICRF-187）双二氧哌嗪类似物与 DNA 拓扑异构酶 II 抑制作用保护心肌细胞能力的定量构效关系研究。
Toxicol Appl Pharmacol. 2020 Jul 15;399:115038. doi: 10.1016/j.taap.2020.115038. Epub 2020 May 15.
3
Resveratrol protects against PM2.5-induced heart defects in zebrafish embryos as an antioxidant rather than as an AHR antagonist.白藜芦醇作为一种抗氧化剂而非 AHR 拮抗剂，可预防 PM2.5 诱导的斑马鱼胚胎心脏缺陷。
Toxicol Appl Pharmacol. 2020 Jul 1;398:115029. doi: 10.1016/j.taap.2020.115029. Epub 2020 May 5.
4
A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm.一种用于评估 hERG 阻断效力的系统策略及其在新的心脏安全性范式中的意义。
Toxicol Appl Pharmacol. 2020 May 1;394:114961. doi: 10.1016/j.taap.2020.114961. Epub 2020 Mar 21.
5
Combining an in silico proarrhythmic risk assay with a tPKPD model to predict QTc interval prolongation in the anesthetized guinea pig assay.结合计算机致心律失常风险测定和 tPKPD 模型预测麻醉豚鼠试验中的 QTc 间期延长。
Toxicol Appl Pharmacol. 2020 Mar 1;390:114883. doi: 10.1016/j.taap.2020.114883. Epub 2020 Jan 23.
6
Low doses of BPA induced abnormal mitochondrial fission and hypertrophy in human embryonic stem cell-derived cardiomyocytes via the calcineurin-DRP1 signaling pathway: A comparison between XX and XY cardiomyocytes.低剂量双酚 A 通过钙调神经磷酸酶-DRP1 信号通路诱导人胚胎干细胞源性心肌细胞线粒体裂变和肥大：XX 和 XY 心肌细胞的比较。
Toxicol Appl Pharmacol. 2020 Feb 1;388:114850. doi: 10.1016/j.taap.2019.114850. Epub 2019 Dec 9.
7
Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms.工作坊报告：FDA 关于利用与人类相关的平台改善心脏毒性评估的工作坊。
Circ Res. 2019 Oct 11;125(9):855-867. doi: 10.1161/CIRCRESAHA.119.315378. Epub 2019 Oct 10.
8
Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development.临床前药物研发：从药物开发的革命角度看
**解析**：原文为一篇医学相关的学术论文，因此译文也应该尽量贴近学术风格。Clinical Trials in a Dish 直译是“在培养皿中的临床试验”，但结合文章上下文，可以理解为“临床前药物研发”，即新药在进入临床试验之前的研究阶段。因此将标题译为“临床前药物研发：从药物开发的革命角度看”。
SLAS Discov. 2018 Sep;23(8):765-776. doi: 10.1177/2472555218775028. Epub 2018 Jun 4.
9
Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.因药物不良反应导致462种药品上市后撤市：对世界文献的系统评价
BMC Med. 2016 Feb 4;14:10. doi: 10.1186/s12916-016-0553-2.
10
Relationships between fine particulate air pollution, cardiometabolic disorders, and cardiovascular mortality.细颗粒物空气污染与心血管代谢紊乱和心血管死亡率的关系。
Circ Res. 2015 Jan 2;116(1):108-15. doi: 10.1161/CIRCRESAHA.116.305060. Epub 2014 Oct 27.
Zotero 插件